-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, QiXk4b+vd+tKIqsGhVDTInD1iO9K/fFzM0Vgm0mDxGaQ9N2Ejy9hvnLlV2JAweo7 fCK7/sSr3xz8cTbvwbQN9g== 0001437749-10-003916.txt : 20101115 0001437749-10-003916.hdr.sgml : 20101115 20101115112126 ACCESSION NUMBER: 0001437749-10-003916 CONFORMED SUBMISSION TYPE: NT 10-Q PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20100930 FILED AS OF DATE: 20101115 DATE AS OF CHANGE: 20101115 EFFECTIVENESS DATE: 20101115 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IMMUNOSYN CORP CENTRAL INDEX KEY: 0001375623 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 205322896 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: NT 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-52871 FILM NUMBER: 101190033 BUSINESS ADDRESS: STREET 1: 4225 EXECUTIVE SQUARE SUITE 260 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: 858-200-2320 MAIL ADDRESS: STREET 1: 4225 EXECUTIVE SQUARE SUITE 260 CITY: LA JOLLA STATE: CA ZIP: 92037 NT 10-Q 1 immunosyn_nt10q-093010.htm FORM 12B-25 immunosyn_nt10q-093010.htm
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 12b-25

NOTIFICATION OF LATE FILING
(Check one): ¨Form 10-K   ¨Form 20-F   ¨Form 11-K   xForm 10-Q   ¨Form 10-D   ¨Form N-SAR ¨Form N-CSR

For Period Ended: September 30, 2010
     
¨
  
Transition Report on Form 10-K
¨
  
Transition Report on Form 20-F
¨
  
Transition Report on Form 11-K
¨
  
Transition Report on Form 10-Q
¨
  
Transition Report on Form N-SAR

For the Transition Period Ended: ____________________
 
Read Instruction (on back page) Before Preparing Form. Please Print or Type.
 
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
 
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
 

PART I — REGISTRANT INFORMATION

Immunosyn Corporation
Full Name of Registrant

N/A
Former Name if Applicable

10815 Rancho Bernardo Road, Suite 100
Address of Principal Executive Office (Street and Number)

San Diego, CA  92127
City, State and Zip Code

 
 
 
 
PART II — RULE 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)
 
x
    
(a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
(b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
(c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 
PART III — NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.  (Attach extra Sheets if Needed)
 
Immunosyn Corporation is seeking the extension due to its inability to complete the financial statements and related discussion and analysis for the fiscal quarter ended September 30, 2010 in a timely manner as a result of  technology issues and not having  the financial resources to engage appropriate personnel and outside services to assist in such efforts.

 
PART IV — OTHER INFORMATION
 
(1)
  
Name and telephone number of person to contact in regard to this notification
       
   
Douglas McClain, Jr.                (888) 853-3663
  
   
(Name)                       (Area Code) (Telephone Number)
  
       
(2)
  
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
Yes x No ¨
     
       
(3)
  
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? Yes ¨ No x
       
   
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 
 
 

Immunosyn Corporation
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
       
Date: November 15, 2010
By:  
 /s/ Douglas McClain, Jr.  
   
Douglas McClain, Jr.
Chief Financial and Accounting Officer

INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.
 
ATTENTION
Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).
 

 
 -----END PRIVACY-ENHANCED MESSAGE-----